19.56
0.42 (2.19%)
| Penutupan Terdahulu | 19.14 |
| Buka | 19.26 |
| Jumlah Dagangan | 1,616,626 |
| Purata Dagangan (3B) | 2,439,230 |
| Modal Pasaran | 3,612,527,872 |
| Harga / Pendapatan (P/E Ke hadapan) | 51.81 |
| Harga / Jualan (P/S) | 3.88 |
| Harga / Buku (P/B) | 3.50 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Mar 2026 |
| Margin Keuntungan | -29.95% |
| Margin Operasi (TTM) | -25.97% |
| EPS Cair (TTM) | -1.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 107.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 35.65% |
| Nisbah Semasa (MRQ) | 5.20 |
| Aliran Tunai Operasi (OCF TTM) | -263.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -202.32 M |
| Pulangan Atas Aset (ROA TTM) | -8.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Legend Biotech Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 1.88 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.31% |
| % Dimiliki oleh Institusi | 47.92% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Davern Capital Partners, Lp | 31 Dec 2025 | 1,056,668 |
| Matthews International Capital Management Llc | 31 Dec 2025 | 956,824 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 80.00 (Barclays, 309.00%) | Beli |
| Median | 62.00 (216.97%) | |
| Rendah | 21.00 (TD Cowen, 7.36%) | Pegang |
| Purata | 58.71 (200.15%) | |
| Jumlah | 6 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 19.80 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 11 Mar 2026 | 49.00 (150.51%) | Beli | 19.56 |
| RBC Capital | 11 Mar 2026 | 62.00 (216.97%) | Beli | 19.56 |
| 20 Jan 2026 | 66.00 (237.42%) | Beli | 23.42 | |
| Barclays | 04 Feb 2026 | 80.00 (309.00%) | Beli | 16.65 |
| HC Wainwright & Co. | 22 Jan 2026 | 50.00 (155.62%) | Beli | 19.34 |
| TD Cowen | 22 Jan 2026 | 21.00 (7.36%) | Pegang | 19.34 |
| Oppenheimer | 07 Jan 2026 | 75.00 (283.44%) | Beli | 22.72 |
| Cantor Fitzgerald | 17 Dec 2025 | 74.00 (278.32%) | Beli | 21.42 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 Jan 2026 | Pengumuman | Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use |
| 12 Jan 2026 | Pengumuman | Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference |
| 17 Dec 2025 | Pengumuman | Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |